24/7 Market News Snapshot 25 September, 2025 – PepGen Inc. Common Stock (NASDAQ:PEPG)
DENVER, Colo., 25 September, 2025 (www.247marketnews.com) – (NASDAQ:PEPG) are discussed in this article.
PepGen Inc., a clinical-stage biotechnology company focused on pioneering oligonucleotide therapies, has experienced significant market activity, opening the day at $5.90 before dropping to $5.095, reflecting a dramatic increase of over 91.54% from its previous closing price of $2.66. This volatility has garnered intense interest, evidenced by a trading volume of approximately 83.78 million shares. The sudden price swing highlights potential investment opportunities for traders closely monitoring this biotech entity.
In a strategic move to bolster its financial standing, PepGen also announced the pricing of its underwritten offering of 31,250,000 shares of common stock at $3.20 per share, expected to yield gross proceeds of around $100 million before deducting underwriting fees and other costs. This offering is slated to close on or about September 26, 2025, pending customary closing conditions. To further support its growth trajectory, the company has provided underwriters with a 30-day option to acquire an additional 4,687,500 shares at the public offering price, which would enhance its capital potential.
The funds generated from this offering are earmarked for accelerating PepGen’s research initiatives, particularly the ongoing FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, alongside enhancing operational capacity and funding other corporate activities. Leveraging over a decade of research, PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform aims to address critical neuromuscular and neurological conditions, significantly improving the efficiency of therapeutic agents.
As PepGen advances its mission, these developments underlie the company’s commitment to transforming treatment paradigms in severe diseases, while investors are encouraged to consider the associated risks and uncertainties outlined in their SEC filings. The firm’s securities are registered under a statement filed with the Securities and Exchange Commission (SEC), effective July 8, 2024, with further documentation available through the SEC’s website.